Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 12Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 2Triple Negative Breast Neoplasms 1Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Neurofibrosarcoma 1Neuroendocrine Tumors 1Neoplasms 1Myeloproliferative Disorders 1Melanoma 1Leukemia, Myeloid, Chronic-Phase 1Cytopenia 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Breast Neoplasms 1BRCA1 Mutation 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1Accelerated Phase Myeloproliferative Neoplasm 1

Interventions

Cyclophosphamide 72fludarabine phosphate 64Peripheral Blood Stem Cell Transplantation 64Busulfan 50Cyclosporine 48Mycophenolic Acid 45Tacrolimus 41Antilymphocyte Serum 41Radiotherapy 37Whole-Body Irradiation 33Methotrexate 33Filgrastim 33Imatinib Mesylate 27Methylprednisolone 25Cord Blood Stem Cell Transplantation 24Melphalan 22Dasatinib 16sargramostim 15Etoposide 15nilotinib 14Cytarabine 14Interferon-alpha 13Therapeutics 11Flow Cytometry 11Cyclosporins 11Thiotepa 9Sirolimus 9Alemtuzumab 9Polymerase Chain Reaction 8Psychiatric Rehabilitation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Chronic-Phase × decitabine and cedazuridine drug combination × Clear all
NCT05007873 2026-02-18

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
70 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡